company background image
TLT logo

Theralase Technologies TSXV:TLT Stock Report

Last Price

CA$0.28

Market Cap

CA$68.1m

7D

10.0%

1Y

71.9%

Updated

31 Jan, 2025

Data

Company Financials +

Theralase Technologies Inc.

TSXV:TLT Stock Report

Market Cap: CA$68.1m

TLT Stock Overview

A clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. More details

TLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 60.19% per year

Earnings have grown 10.1% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (CA$987K)

Does not have a meaningful market cap (CA$68M)

Volatile share price over the past 3 months compared to the Canadian market


My Notes

Capture your thoughts, links and company narrative

Theralase Technologies Inc. Competitors

Aurora Spine

TSXV:ASG

CA$34.1m

Nanalysis Scientific

TSXV:NSCI

CA$35.1m

Perimeter Medical Imaging AI

TSXV:PINK

CA$55.2m

Profound Medical

TSX:PRN

CA$279.9m

Price History & Performance

Summary of share price highs, lows and changes for Theralase Technologies
Historical stock prices
Current Share PriceCA$0.28
52 Week HighCA$0.38
52 Week LowCA$0.14
Beta1.17
1 Month Change3.77%
3 Month Change5.77%
1 Year Change71.88%
3 Year Change-30.38%
5 Year Change1.85%
Change since IPO-70.43%

Recent News & Updates

Recent updates

Is Theralase Technologies (CVE:TLT) In A Good Position To Deliver On Growth Plans?

Jul 29
Is Theralase Technologies (CVE:TLT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Theralase Technologies' (CVE:TLT) Cash Burn Rate

Apr 08
We're Not Very Worried About Theralase Technologies' (CVE:TLT) Cash Burn Rate

Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Dec 24
Here's Why We're Not Too Worried About Theralase Technologies' (CVE:TLT) Cash Burn Situation

Shareholder Returns

TLTCA Medical EquipmentCA Market
7D10.0%-2.4%-0.5%
1Y71.9%-16.0%17.7%

Return vs Industry: TLT exceeded the Canadian Medical Equipment industry which returned -17.9% over the past year.

Return vs Market: TLT exceeded the Canadian Market which returned 17.9% over the past year.

Price Volatility

Is TLT's price volatile compared to industry and market?
TLT volatility
TLT Average Weekly Movement14.0%
Medical Equipment Industry Average Movement13.8%
Market Average Movement8.4%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market2.9%

Stable Share Price: TLT's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: TLT's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aRoger Dumoulin-Whitewww.theralase.com

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.

Theralase Technologies Inc. Fundamentals Summary

How do Theralase Technologies's earnings and revenue compare to its market cap?
TLT fundamental statistics
Market capCA$68.14m
Earnings (TTM)-CA$4.33m
Revenue (TTM)CA$986.60k

69.1x

P/S Ratio

-15.7x

P/E Ratio

Is TLT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLT income statement (TTM)
RevenueCA$986.60k
Cost of RevenueCA$476.43k
Gross ProfitCA$510.17k
Other ExpensesCA$4.84m
Earnings-CA$4.33m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.017
Gross Margin51.71%
Net Profit Margin-438.78%
Debt/Equity Ratio0%

How did TLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 05:42
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theralase Technologies Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeEchelon Wealth Partners Inc.
Andre UddinResearch Capital Corporation